Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: tirzepatide versus dulaglutide for major cardiovascular events in type 2 diabetes
NL-OMON52730Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide and dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Oct 2020; status: active, not recruiting.
02
Drugs
tirzepatidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON52730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52730.